Physician profile
Sanul Corrielus
NPI 1205831716
$37,653.03
in general payments reported to CMS, 2019-2025
27 companies · $1,499 in 2025
The $1,499 reported for 2025 was more than what 78% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,287 · 2020: $9,412 · 2021: $6,336 · 2022: $10K · 2023: $6,315 · 2024: $2,518 · 2025: $1,499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,616 · Travel and Lodging: $2,626 · Consulting Fee: $2,590 · Grant: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,615.64 |
| Travel and Lodging | $2,626.20 |
| Consulting Fee | $2,590.00 |
| Grant | $1,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $14,147.65 | 2020-2022 | |
| Medtronic, INC. | $8,473.23 | 2020-2025 | Symplicity G3, Onyx Frontier |
| Boston Scientific Corporation | $3,852.01 | 2019-2024 | Watchman Access System, Watchman Flx, Watchman |
| E.R. Squibb & Sons, L.L.C. | $2,590.00 | 2023 | |
| Akcea Therapeutics, INC. | $2,303.38 | 2020-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,825.69 | 2024-2025 | Lifevest |
| Medtronic Vascular, INC. | $1,556.37 | 2019-2020 | |
| Esperion Therapeutics, INC. | $879.52 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $633.57 | 2021-2025 | Jardiance |
| Abiomed | $295.38 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $172.91 | 2019-2024 | Amvuttra |
| Smith+Nephew, INC. | $148.46 | 2022 | |
| Heartflow, INC. | $132.77 | 2022 | |
| Edwards Lifesciences Corporation | $130.16 | 2019 | |
| Livanova USA, INC. | $105.89 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $84.26 | 2021 | |
| Novartis Pharmaceuticals Corporation | $62.99 | 2020-2021 | |
| Abbott Laboratories | $57.37 | 2023-2025 | Jot Dx |
| Scpharmaceuticals INC. | $36.77 | 2023-2024 | |
| Acarix USA INC. | $31.01 | 2023 | Cadscor System, Cadscor System |
| Bardy Diagnostics, INC. | $25.00 | 2020 | |
| Janssen Pharmaceuticals, INC | $24.64 | 2021 | |
| Kestra Medical Technology Services, INC. | $24.56 | 2024 | Assure Wcd |
| Canon Medical Systems USA, INC. | $24.00 | 2025 | Ct Scanner |
| Medicomp INC | $22.02 | 2021 | |
| Amarin Pharma, INC. | $13.42 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanul Corrielus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.